Cargando…
Costo per responder di risankizumab e secukinumab nel trattamento della psoriasi a placche da moderata a grave in Italia
PURPOSE: The objective of this analysis was to compare the cost per responder between risankizumab and secukinumab among patients with moderate-to-severe plaque psoriasis in Italy. METHODS: The clinical efficacy was assessed based on IMMerge study of published efficacy data as measured by Psoriasis...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AboutScience
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616179/ https://www.ncbi.nlm.nih.gov/pubmed/36627874 http://dx.doi.org/10.33393/grhta.2021.2258 |